Presentation Operator Good morning, and welcome to the Interpublic Group 4th-Quarter and Full-Year 2024 Conference Call. All ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company’s ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...

Scott Ullem; Chief Financial Officer, Corporate Vice President; Edwards Lifesciences Corp Daveen Chopra; Corporate Vice President - Surgical Structural Heart; Edwards Lifesciences Corp Larry Wood ...

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 28% in three years, versus a market return of ...

Edwards Lifesciences Corp. closed 21.12% short of its 52-week high of $96.12, which the company reached on March 28th.